MDxHealth (NASDAQ:MDXH) Raised to “Sell” at Wall Street Zen

MDxHealth (NASDAQ:MDXH) was upgraded by stock analysts at Wall Street Zen to a “sell” rating in a report issued on Saturday.

A number of other research firms also recently issued reports on MDXH. Lake Street Capital set a $3.00 price target on shares of MDxHealth and gave the company a “buy” rating in a research note on Friday. William Blair cut shares of MDxHealth from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 14th. BTIG Research reduced their target price on shares of MDxHealth from $7.00 to $4.00 and set a “buy” rating on the stock in a report on Thursday, May 14th. Finally, TD Cowen restated a “buy” rating and issued a $1.50 target price (down from $7.00) on shares of MDxHealth in a report on Thursday, May 14th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $2.83.

MDxHealth Price Performance

Shares of MDXH opened at $0.81 on Friday. The stock has a market capitalization of $40.00 million, a price-to-earnings ratio of -1.12 and a beta of 1.42. MDxHealth has a 1 year low of $0.40 and a 1 year high of $5.33. The business’s 50 day simple moving average is $0.47 and its 200-day simple moving average is $1.77.

MDxHealth (NASDAQ:MDXH) last posted its earnings results on Thursday, August 13th. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.01. The firm had revenue of $27.21 million for the quarter, compared to the consensus estimate of $26.14 million. On average, sell-side analysts expect that MDxHealth will post -0.6 earnings per share for the current year.

Institutional Trading of MDxHealth

A number of institutional investors have recently bought and sold shares of MDXH. Perkins Capital Management Inc. boosted its stake in MDxHealth by 7.1% during the first quarter. Perkins Capital Management Inc. now owns 1,476,441 shares of the company’s stock worth $3,396,000 after buying an additional 97,500 shares during the period. Kennedy Capital Management LLC bought a new stake in shares of MDxHealth in the 3rd quarter worth about $1,826,000. FreeGulliver LLC lifted its holdings in shares of MDxHealth by 25.7% in the 4th quarter. FreeGulliver LLC now owns 317,894 shares of the company’s stock worth $1,135,000 after acquiring an additional 65,000 shares during the last quarter. Renaissance Technologies LLC boosted its stake in shares of MDxHealth by 21.8% during the 1st quarter. Renaissance Technologies LLC now owns 304,700 shares of the company’s stock worth $701,000 after purchasing an additional 54,600 shares during the period. Finally, Mink Brook Asset Management LLC boosted its stake in shares of MDxHealth by 64.9% during the 4th quarter. Mink Brook Asset Management LLC now owns 263,420 shares of the company’s stock worth $940,000 after purchasing an additional 103,686 shares during the period.

Key MDxHealth News

Here are the key news stories impacting MDxHealth this week:

• Positive Sentiment: MDxHealth reported second-quarter revenue of $27.2 million, up 16% year over year and above the approximately $26.1 million analyst estimate. The company’s $0.18 per-share loss was slightly better than the $0.19 consensus cited by MarketBeat, although another estimate tracked by Zacks showed a larger expected loss of $0.12. MDxHealth Reports Second Quarter 2026 Financial Results
• Positive Sentiment: The company raised or reaffirmed an optimistic FY 2026 revenue outlook of $110 million to $115 million, well above the roughly $98.8 million consensus estimate. This suggests management expects continued commercial momentum. MDxHealth Earnings Report
• Positive Sentiment: Management discussed the results and outlook during its second-quarter earnings call, giving investors additional detail on the company’s operating performance and growth plans. MDxHealth Q2 2026 Earnings Call Transcript
• Neutral Sentiment: Trading in MDXH was temporarily paused several times under the exchange’s Limit Up-Limit Down mechanism. The halts do not represent a fundamental company announcement, but they underscore unusually high volatility and speculative trading activity.
• Negative Sentiment: MDxHealth agreed to raise $20 million through a direct share offering. The added funding may support operations and growth, but issuing new shares can dilute existing shareholders and may be contributing to the sharp price swings. MDxHealth Raises $20 Million in Direct Share Offering

About MDxHealth

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.